Business
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review
About this update from Spero Therapeutics, Inc.
[{"type":"image","alt":"Spero Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Spero Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NZ7Kj4X.syHvrTwbJDWHqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the program","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"SPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company’s pipeline in Q1 2025 ","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 ","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":706,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.","length":396,"tagName":"p"},{"type":"text","content":""Spero is focused on the execution of the tebipenem HBr clinical program, including preparing for the pre-specified interim analysis next quarter,” said Esther Rajavelu, Interim President and Chief Executive Officer. “We believe that, if approved, tebipenem HBr could address a critical unmet need for an oral ca...